Axovant Sciences Ltd (AXGT) Stock Price, Forecast & Analysis

NASDAQ:AXGT

2.1
-0.05 (-2.33%)
At close: Nov 12, 2020
2.1
0 (0%)
After Hours: 11/12/2020, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

AXGT Key Statistics, Chart & Performance

Key Statistics
Market Cap99.22M
Revenue(TTM)N/A
Net Income(TTM)-53.16M
Shares47.25M
Float29.49M
52 Week High6.12
52 Week Low1.41
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.97
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
AXGT short term performance overview.The bars show the price performance of AXGT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

AXGT long term performance overview.The bars show the price performance of AXGT in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of AXGT is 2.1 null. In the past month the price decreased by -38.95%. In the past year, price decreased by -55.32%.

Axovant Sciences Ltd / AXGT Daily stock chart

AXGT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
AXGT Full Technical Analysis Report

AXGT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to AXGT. Both the profitability and financial health of AXGT have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AXGT Full Fundamental Analysis Report

AXGT Financial Highlights

Over the last trailing twelve months AXGT reported a non-GAAP Earnings per Share(EPS) of -1.9699999999999998. The EPS increased by 67.6% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -74.84%
ROE N/A
Debt/Equity 0.11
Chartmill High Growth Momentum
EPS Q2Q%83.74%
Sales Q2Q%N/A
EPS 1Y (TTM)67.6%
Revenue 1Y (TTM)N/A
AXGT financials

AXGT Forecast & Estimates


Analysts
Analysts92
Price TargetN/A
EPS Next Y63.48%
Revenue Next YearN/A
AXGT Analyst EstimatesAXGT Analyst Ratings

AXGT Ownership

Ownership
Inst Owners0%
Ins Owners39.32%
Short Float %N/A
Short RatioN/A
AXGT Ownership

About AXGT

Company Profile

Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.

Company Info

Axovant Sciences Ltd

11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR

LONDON X0 10036

CEO: Pavan Cheruvu

Phone: 833-296-8268

Axovant Sciences Ltd / AXGT FAQ

What does Axovant Sciences Ltd do?

Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.


What is the stock price of Axovant Sciences Ltd today?

The current stock price of AXGT is 2.1 null. The price decreased by -2.33% in the last trading session.


Does Axovant Sciences Ltd pay dividends?

AXGT does not pay a dividend.


What is the ChartMill technical and fundamental rating of AXGT stock?

AXGT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the PE ratio for AXGT stock?

Axovant Sciences Ltd (AXGT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.97).